Dr. Jouille's expertise: 30 years of dermatological innovation
Dr Alain Jouille is a graduate of Bordeaux University of Medicine and began his career in the pharmaceutical industry in France and abroad. After 15 years in this field, he decided to leave his executive position to set up his own company, Le Laboratoire de Dr Jouille, to develop innovative professional products and materials for chiropodists, in particular a range of cosmetics (later acquired by the L'Oréal group).
Another emblematic product was also developed to meet the needs of professionals treating plantar warts. Marketed under the brand name "Verrucide du Dr JOUILLE” before being rebranded as "VERCID", the product has now been available for thirty years and is the go-to product for chiropodists.
From human medicine to equine health
Reading a scientific publication revealed the existence of a tumour, known as a sarcoid, that was proving particularly difficult to treat in horses. Although different, it has similarities with human warts.
The impossibility of applying dressings to a horse's skin meant that product had to be reformulated so that it could be applied directly to the tumour and would adhere.
Convincing clinical results
After a few months of testing on around twenty horses suffering from sarcoid tumours, the product proved to be exceptionally beneficial with great results obtained in all areas: efficacy, speed of action, tolerance, ease of use and cost of treatment.
Due to its specific nature, the product is marketed under the brand name SERKYL.
Serkyl, the benchmark in the treatment of equine sarcoids
SERKYL is marketed in partnership with the company "Cheval Energy", one of the key players in the equine health market. Over the last few years, SERKYL has gradually established itself as the benchmark product in the treatment of skin tumours in horses (sarcoids, papilloma virus tumours), as demonstrated by the many testimonials from users.
Featuring in leading magazines such as « P.V.E. » and « Cheval Magasine », SERKYL has been widely adopted by owners and carers of horses affected by skin tumours.
Scientific recognition and perspectives
As a partner in the HIPPOLIA France cluster, SERKYL should be at the heart of a major multinational scientific study to confirm its full potential.
Notre recommandation
The current recommendation is to avoid delays in treating a sarcoid tumour. Treat it with SERKYL as soon as it appears, and you'll be sure of treating it in just a few days, with no residual scarring.